|
68 Companies |
|
87 Products |
|
87 Products |
|
71 Mechanisms of Action |
|
3 Trials |
|
597 News |
|
| «12345678910111213» |
- Amevive (alefacept) / Astellas
Trial suspension: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=5, Suspended, Sponsor: Emory University
Recruiting --> Suspended
- | Altabax (retapamulin) / GSK, Almirall
Enrollment change: Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis (clinicaltrials.gov) - Mar 29, 2012
P4, N=29, Completed, Sponsor: Derm Research, PLLC
Recruiting --> Suspended N=40 --> 29
- Clinical: Narrowband UVB for Children With Moderate to Severe Atopic Eczema (clinicaltrials.gov) - Mar 29, 2012
P=N/A, N=58, Completed, Sponsor: Royal Victoria Infirmary
- ||||| cobamamide liposomal (HL009) / Daewoong Pharma
New P2 trial: Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Mar 29, 2012
P2, N=120, Completed, Sponsor: HanAll BioPharma Co., Ltd.
- | Altabax (retapamulin) / GSK, Almirall
Trial completion: Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis (clinicaltrials.gov) - Mar 29, 2012
P4, N=29, Completed, Sponsor: Derm Research, PLLC
N=40 --> 29 Recruiting --> Completed
- recombinant ectodysplasin A1 (APO200) / Onxeo, Pierre Fabre
New P1 trial: A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200 (clinicaltrials.gov) - Mar 25, 2012
P1, N=6, Completed, Sponsor: Edimer Pharmaceuticals
- | ligelizumab (QGE 031) / Novartis
New P2 trial: A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients (clinicaltrials.gov) - Mar 11, 2012
P2, N=22, Completed, Sponsor: Novartis Pharmaceuticals
- |||| Trial completion, Metastases: Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application (clinicaltrials.gov) - Mar 8, 2012
P4, N=74, Completed, Sponsor: Galderma Brasil Ltda.
Recruiting --> Completed Recruiting --> Completed
- ||||| Dupixent (dupilumab) / Sanofi, Regeneron
New P2 trial: Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Mar 6, 2012
P2, N=109, Completed, Sponsor: Regeneron Pharmaceuticals
- | Trial completion, Review: Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=11, Completed, Sponsor: Edimer Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- ||| MEDI 4212 / AstraZeneca
New P1 trial: A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL (clinicaltrials.gov) - Mar 1, 2012
P1, N=86, Completed, Sponsor: MedImmune LLC
- Enrollment change: Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunwald-giemsa Stained Tissue Smear (clinicaltrials.gov) - Feb 8, 2012
P=N/A, N=66, Completed, Sponsor: Norwegian University of Science and Technology
Recruiting --> Completed N=38 --> 66
- New P2 trial: A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Feb 6, 2012
P2, N=0, Withdrawn, Sponsor: Healthpoint
- |||||||||| betamethasone/dexchlorpheniramine maleate / Generic mfg., prednisolone / Generic mfg.
New P3 trial: Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment (clinicaltrials.gov) - Feb 6, 2012
P3, N=140, Not yet recruiting, Sponsor: EMS
- Trial termination: Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=7, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
N=38 --> 66 Recruiting --> Terminated; Competing studies
- Enrollment change: Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=7, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Terminated; Competing studies N=30 --> 7
- New P4 trial: The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) (clinicaltrials.gov) - Feb 5, 2012
P4, N=6, Completed, Sponsor: Maastricht University Medical Center
- timbetasin topical (RGN-137) / RegeneRx
Trial termination: A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jan 25, 2012
P2, N=30, Terminated, Sponsor: RegeneRx Biopharmaceuticals, Inc.
N=30 --> 7 Completed --> Terminated; Lack of patient availability and expiration of study drug
- | montelukast / Generic mfg.
Trial initiation date: Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens (clinicaltrials.gov) - Jan 24, 2012
P4, N=20, Completed, Sponsor: 1st Allergy & Clinical Research Center
Completed --> Terminated; Lack of patient availability and expiration of study drug Initiation date: Nov 2007 --> Mar 2008
- | Enrollment change: Investigation of Efficacy and Safety of EPOGAM (clinicaltrials.gov) - Jan 24, 2012
P4, N=23, Completed, Sponsor: Max Zeller Soehne AG
Initiation date: Nov 2007 --> Mar 2008 N=30 --> 23
- | Trial completion: Investigation of Efficacy and Safety of EPOGAM (clinicaltrials.gov) - Jan 24, 2012
P4, N=23, Completed, Sponsor: Max Zeller Soehne AG
N=30 --> 23 Recruiting --> Completed
- | montelukast / Generic mfg.
Trial completion: Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens (clinicaltrials.gov) - Jan 24, 2012
P4, N=20, Completed, Sponsor: 1st Allergy & Clinical Research Center
Recruiting --> Completed Recruiting --> Completed
- pirfenidone / Generic mfg.
Enrollment closed: Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Jan 23, 2012
P2, N=35, Active, not recruiting, Sponsor: William Gahl
Recruiting --> Completed Terminated --> Active, not recruiting
- | DPK 060 / DermaGen
New P1/2 trial: A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060 (clinicaltrials.gov) - Jan 19, 2012
P1/2, N=41, Completed, Sponsor: DermaGen AB
- Xolair (omalizumab) / Roche, Novartis
Biomarker, Trial completion: AMB-WEI-1052-I: Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage (clinicaltrials.gov) - Jan 8, 2012
P2, N=0, Completed, Sponsor: Technische Universit
Terminated --> Active, not recruiting Recruiting --> Completed
- ||| colchicine / Generic mfg.
Trial completion: Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients (clinicaltrials.gov) - Jan 8, 2012
P1, N=75, Completed, Sponsor: Mutual Pharmaceutical Company, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- gevokizumab (S 78989) / Novartis
Trial withdrawal: A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease (clinicaltrials.gov) - Dec 29, 2011
P1/2, N=0, Withdrawn, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Active, not recruiting --> Completed Completed --> Withdrawn
- gevokizumab (S 78989) / Novartis
Enrollment change: A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease (clinicaltrials.gov) - Dec 29, 2011
P1/2, N=0, Withdrawn, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed --> Withdrawn N=21 --> 0
- New P3 trial: Probiotics in Adults: do They Improve Atopic Dermatitis? (clinicaltrials.gov) - Dec 20, 2011
P3, N=48, Completed, Sponsor: Ospedale L. Sacco – Polo Universitario
- | JNJ-39758979 / J&J
New P2 trial: A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis (clinicaltrials.gov) - Dec 20, 2011
P2, N=88, Terminated, Sponsor: Janssen Pharmaceutical K.K.
- | Eucrisa (crisaborole) / Pfizer, AN2898 / Pfizer
Enrollment change: Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis (clinicaltrials.gov) - Dec 12, 2011
P2, N=46, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
N=21 --> 0 N=80 --> 46
- | Eucrisa (crisaborole) / Pfizer, AN2898 / Pfizer
Trial completion: Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis (clinicaltrials.gov) - Dec 12, 2011
P2, N=46, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
N=80 --> 46 Active, not recruiting --> Completed
- Trial completion: Natural History of Asphyxiating Thoracic Dystrophy (DTJ) (clinicaltrials.gov) - Dec 11, 2011
P=N/A, N=50, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Recruiting --> Completed
- | lenalidomide / Generic mfg.
Trial initiation date: LENAKAP: Lenalidomide in Kaposi Disease Associated With HIV Infection (clinicaltrials.gov) - Dec 8, 2011
P2, N=35, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Recruiting --> Completed Initiation date: Jul 2011 --> Oct 2011
- pirfenidone / Generic mfg.
Trial initiation date: Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Dec 4, 2011
P2, N=35, Active, not recruiting, Sponsor: William Gahl
Initiation date: Jul 2011 --> Oct 2011 Initiation date: Mar 1997 --> Sep 2005
- pirfenidone / Generic mfg.
Enrollment change: Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Dec 4, 2011
P2, N=35, Active, not recruiting, Sponsor: William Gahl
Initiation date: Mar 1997 --> Sep 2005 N=58 --> 35
- ||| Enrollment change: Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC) (clinicaltrials.gov) - Nov 15, 2011
P2, N=122, Completed, Sponsor: Taisho Pharmaceutical R&D Inc.
N=58 --> 35 N=240 --> 122
- |||| Trial completion: Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC) (clinicaltrials.gov) - Nov 15, 2011
P2, N=122, Completed, Sponsor: Taisho Pharmaceutical R&D Inc.
N=240 --> 122 Active, not recruiting --> Completed
- Clinical: Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis (clinicaltrials.gov) - Nov 8, 2011
P=N/A, N=10, Recruiting, Sponsor: Wake Forest School of Medicine
- | Chanllergen (dermatophagoides farinae sublingual drops) - Zhejiang Wolwo Bio / Pharma
New P2 trial: Sublingual Immunotherapy in Patients With Atopic Dermatitis (clinicaltrials.gov) - Nov 8, 2011
P2, N=240, Recruiting, Sponsor: Zhejiang University
- |||||||||| Desonate (desonide gel) / LEO Pharma
New P3 trial: Efficacy Emollient on Xerosis in Children With Atopic Dermatitis (clinicaltrials.gov) - Nov 6, 2011
P3, N=251, Completed, Sponsor: Pierre Fabre Medicament
- Trial completion: Effect of Dietary Phospholipids on Atopic Dermatitis (clinicaltrials.gov) - Nov 6, 2011
P=N/A, N=39, Completed, Sponsor: University of Jena
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| lotamilast 0.5% ointment (DMVT-501 0.5% ointment) / Roivant
New P2 trial: A Phase 2 Study of E6005 in Patients With Atopic Dermatitis (clinicaltrials.gov) - Oct 26, 2011
P2, N=78, Completed, Sponsor: Eisai Co., Ltd.
- Trial completion: Genetics: Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis (clinicaltrials.gov) - Oct 5, 2011
P=N/A, N=900, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Completed
- LEO 29102 / LEO Pharma
New P1 trial: Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. (clinicaltrials.gov) - Oct 4, 2011
P1, N=58, Terminated, Sponsor: LEO Pharma
- Trial termination: Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions (clinicaltrials.gov) - Oct 2, 2011
P1/2, N=50, Terminated, Sponsor: University of Michigan
Recruiting --> Completed Active, not recruiting --> Terminated; Slow enrollment
- ||||||| fexofenadine / Generic mfg.
Trial completion: Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD) (clinicaltrials.gov) - Sep 12, 2011
P2/3, N=100, Completed, Sponsor: Sanofi
Active, not recruiting --> Terminated; Slow enrollment Active, not recruiting --> Completed
- IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Sep 5, 2011
P=N/A, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- ||| LEO 29102 / LEO Pharma
New P1 trial: Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102 (clinicaltrials.gov) - Aug 24, 2011
P1, N=102, Completed, Sponsor: LEO Pharma
- ||| DNK-333 / Novartis
Enrollment change: Safety and Efficacy of DNK333 in Atopic Dermatitis Patients (clinicaltrials.gov) - Aug 23, 2011
P2, N=80, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=60 --> 80